The Philippines became part of an international Ivermectin clinical trials consortium.
On Friday, the Department of Science and Technology (DOST) announced that the Philippines became part of an international consortium that was conducting an analysis of all the randomized Ivermectin clinical trials around the world.
According to DOST Secretary Fortunato “Boy” de la Peña, the global consortium was spearheaded by Dr. Andrew Hill of the Department of Pharmacology and Therapeutics, University of Liverpool in the United Kingdom (UK).
De la Peña said on the DOSTv Facebook page on Friday that the Philippine Ivermectin Clinical Trial Team was part of the International Ivermectin Clinical Trials Consortium which conducted a combined analysis of all the randomized clinical trials of Ivermectin worldwide.
Citing the current available data, de la Peña noted that there were 76 randomized clinical trials evaluating Ivermectin for COVID-19 treatment in more than 20,000 patients in 30 countries.
De la Peña added that there were 11 randomized clinical trials evaluating Ivermectin for prevention in more than 9,000 participants.
De la Peña also said that the country’s team tasked to conduct the clinical trials on the use of the anti-parasitic drug as a treatment for COVID-19 was expected to present its study next week.
“The International Ivermectin Project Team meets at least monthly to connect investigators from around the world researching Ivermectin as a treatment for COVID-19, and their next meeting will be on July 2, 2021 where the Philippine Ivermectin Clinical Trial team will present the study,” de la Peña said.
The eight month-long study was expected to be conducted by a research team from the University of the Philippines (UP) Manila – Philippine General Hospital (PGH) led by Dr. Aileen Wang.
It aimed to provide data on the safety, efficacy, and effect on the viral clearance of the anti-parasitic drug among asymptomatic and non-severe Filipino patients.
What can you say about this? Let us know your thoughts in the comments section below.